



Hanmi Pharmaceutical Co., Ltd.

www.hanmipharm.com

Hanmi Pharm is a global pharmaceutical company focused on the development and commercialization of new pharmaceutical products, with presence in Korea and China. The company's R&D efforts focus on three main areas: 1) new biologics based on LAPSCOVERY platform in diabetes, obesity, NASH and rare diseases; 2) novel targeted agents and 3) novel bispecific antibodies based on PENTAMBODY platform for immuno-oncology and targeted therapy. Hanmi has multiple partnerships and strategic collaborations with leading MNCs and Chinese biopharma companies.

Main Products

Category	Product	Use	Ingredient	Exporting countries
Cardiovascular disease	Amosartan	Hypertension	Amlodipine	CIS
	Amosartan Plus	Hypertension	Amloidpine + Losartan + Chlorthalidone	LATAM
	Amosartan Q	Hypertension, dyslipidemia	Amloidpine + Losartan + Rosuvastatin	LATAM
	Rosuzet	Dyslipidemia	Ezetimibe + Rosuvastatin	CIS, LATAM, SEA
	Amodipin	Hypertension	Amlodipine camsylate	-
	Rovelito	Hypertension, dyslipidemia	Irbesartan + Atorvastatin	LATAM
	Carnitil	Alzheimer's disease, dementia	Acetyl-L-carnitine hydrochloride	-
	Pidogul	Antiplatelet	Clopidogrel napadisilate	MALAYSIA
Gastrointestinal disease	Esomezol	GERD, Gastric ulcer	Esomeprazole strontium	-
Urology	Palpal	Erectile dysfunction	Sildenafil	JAPAN
	Gugu	Erectile dysfunction	Tadalafil	JAPAN
	HANMI TAMS	BPH	Tamsulosin hydrochloride	-
Neurology	Naxozol	Anti-inflammatory	Naproxen + Esomeprazole	-
Ophthalmology, etc	Hyalumini eye drop	Artificial tear, Sjögren's syndrome	Sodium hyaluronate	-
	Rabone D	Osteoporosis	Raloxifene + cholecalciferol	-

CEO
Jong-Soo Woo, Se-Chang Kwon

Location
14, Wiryeseong-daero, Songpa-gu, Seoul, 05545, Korea

Specialty
R&D based pharmaceutical products

Tel / Fax / E-mail
T. 82-2-410-9114

R&D Pipeline

	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
Obesity/ NASH/ Diabetes	LAP ^S Glucagon Combo HM14320 Obesity/Diabetes/NASH	LAP ^S Triple Agonist HM15211 NASH	LAP ^S GLP/GCG HM12525A Obesity	LAP ^S Exd4 Analog Epeglenatide Diabetes	
	LAP ^S Insulin Combo HM14220 Diabetes	LAP ^S Glucagon Analog HM15136 Obesity			
	LAP ^S Insulin148 HM12480 Diabetes	LAP ^S Insulin HM12460A/HM12470 Diabetes			
Oncology	EZH1/2 Inhibitor Solid tumor	Pan-RAF Inhibitor Belvarafenib Solid tumor	Pan-HER Inhibitor Pozitotinib Solid tumor	Oraxol™ Pacitaxel+encequidar Breast cancer, solid tumor	LAP ^S GCSF Analog Eflapegrastim Neutropenia
	LSD1 Inhibitor SCLC, AML	FLT3 Inhibitor HM43239 AML	Oratecan™ Irinotecan+encequidar Solid tumor		
	ADOR Antagonist Solid tumor	PD-1/HER2 BsAb BH2950 Solid tumor	Oradoxel™ Docetaxel+encequidar Solid tumor		
	GBM Stem Cell Therapy HM21001 Glioblastoma	FLX475 (CCR4 Inhibitor) Solid tumor			
	Immuno-oncology BsAb				
	PD-L1/CD47 BsAb				
Rare Diseases/ Other	LAP ^S ASB HM15450 Mucopolysaccharidosis	LAP ^S Glucagon Analog HM15136 Congenital Hyperinsulinism	LAP ^S hGH Epegomatropin GH deficiency		
		LAP ^S GLP-2 Analog HM15912 Short Bowel Syndrome	Luminate® Integrin inhibitor DME		
		Luminate® Integrin inhibitor Retinitis Pigmentosa	BTK Inhibitor HM71224 Autoimmune disease		